Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Net Income towards Common Stockholders (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Net Income towards Common Stockholders for 8 consecutive years, with -$69.2 million as the latest value for Q1 2026.

  • For Q1 2026, Net Income towards Common Stockholders fell 5.57% year-over-year to -$69.2 million; the TTM value through Mar 2026 reached -$315.0 million, down 30.77%, while the annual FY2025 figure was -$311.4 million, 39.08% down from the prior year.
  • Net Income towards Common Stockholders hit -$69.2 million in Q1 2026 for Kymera Therapeutics, up from -$87.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$14.4 million in Q4 2023 and bottomed at -$87.0 million in Q4 2025.
  • Average Net Income towards Common Stockholders over 5 years is -$53.3 million, with a median of -$48.6 million recorded in 2024.
  • Year-over-year, Net Income towards Common Stockholders skyrocketed 58.79% in 2023 and then tumbled 392.43% in 2024.
  • Kymera Therapeutics' Net Income towards Common Stockholders stood at -$34.9 million in 2022, then surged by 58.79% to -$14.4 million in 2023, then tumbled by 392.43% to -$70.8 million in 2024, then decreased by 22.94% to -$87.0 million in 2025, then increased by 20.4% to -$69.2 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$69.2 million, -$87.0 million, and -$82.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.